drugset
drugset / Trial / NCT04070040

Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

NCT04070040 ↗

Phase 2 Recruiting 21 enrolled Beijing Sanbo Brain Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.

Timeline

Start
2020-02-13
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg —

Indications

primary central nervous system lymphoma